联合应用sIL-5Rα及sIL-13Rα2对支气管哮喘小鼠VCAM-1、STAT6水平的影响  

Effects of sIL-5Ra and sIL-13Ra2 on VCAM-1 and STAT6 in bronchial asthma mouse

作　　者：杨学敏[1] 史海广[1] 成家军[1] 李志奎[1] 

机构地区：[1]第四军医大学西京医院呼吸内科,西安710032

出　　处：《国际呼吸杂志》2012年第1期6-9,共4页International Journal of Respiration

基　　金：国家自然科学基金资助项目（30770926）

摘　　要：目的 探讨联合应用可溶性白介素5受体a（sIL-5Ra）及可溶性白介素13受体a2（sIL-13Ra2）对支气管哮喘（简称哮喘）动物血管细胞黏附分子t（VCAM-1）、信号转导和转录激活因子6（STAT6）水平的影响。方法50只BAI。B／c小鼠随机分为正常组、哮喘组、sIL-5Ra治疗组、sIL-13Ra2治疗组、联合sIL-5Ra及sIL-13Rn2治疗组（简称联合治疗组）。哮喘组和治疗组用鸡卵蛋白（OVA）和氢氧化铝致敏，用OVA激发，建立小鼠哮喘模型，正常组用生理盐水代替，其中sIL-5Ra治疗组、sIL-13Ra2治疗组及联合治疗组分别于诱发前30min给予腹腔注射100begsIL-5Ra、sIL-13Ra2及联合应用sIL-5Ra及sIL-13Ra2各100μg，正常组和哮喘组激发前30min给予腹腔注射相同体积生理盐水。ELISA双抗体夹心法测定各组血清VCAM-1水平变化，免疫组织化学法和反转录-聚合酶链反应（RT—PCR）法检测各组小鼠肺组织STAT6水平变化。结果与正常组比较，哮喘组VCAM-1、STAT6含量明显升高（P〈0．01）；联合治疗组可有效降低VCAM-1、STAT6含量，与哮喘组比较差异有统计学意义（P〈0．01）；与单独治疗组相比，联合治疗组效果更明显（P〈0．01）。结论联合应用sIL-5Ra及sIL-13Ra2可显著降低VCAM-1、STAT6含量，从而达到缓解和治疗哮喘的目的。Objective To investigate the effects of soluble interleukin-5 receptor a （sIL-5Ra） and soluble interleukin-13 receptora2 （sIL-13Ra2） on VCAM-1 and STAT6 in bronchial asthma （asthma） animal. Methods A total of 50 BALB/c mice were randomly divided into 5 groups：the normal group, the asthmatic group, the slL-SRa treatment group, the sIL-13Ra2 treatment group, the combination of sIL- 5Ra and sIL-13Ra2 treatment group （the combined treatment group）. Mice in the latter 4 groups were sensitized with ovalbumin （OVA） and A1 （OH）3, and challenged with OVA to establish asthmatic models, while mice in the normal group were treated with saline. Mice in the sIL-5Ra treatment group, the sIL-13Ra2 treatment group and the combined treatment group were injected intraperitoneally with sIL-5Ra （100 μg）,sIL-13Ra （100μg） and the combination of sIL-5Ra （100 μg） and sIL-13Ra2 （100μg） 30 min before challenged, while mice in normal group and asthmatic group received saline. Then the VCAM-1 level of serum were measured by ELISA, and level of STAT6 were measured by immunohistochemically and RT-PCR. Results Compared with the normal group, the level of VCAM-1 and STAT6 in the asthmatic group were higher （ P 〈0.01）. Compared with the asthmatic group, the combined treatment group can effectively reduced VCAM-1 and STAT6 level （ P 〈0.01）. Compared with single treatment, combined treatment group were more effective （ P 〈0.01）. Conclusions sIL-5Ra and slL-13Ra2 inhibit IL-5 and IL-13 functions can re, duce VCAM-1 and STAT6 levels, which achieve the purpose of mitigation and treatment of asthma.

关 键 词：可溶性白介素5受体a 可溶性白介素13受体a2 血管细胞黏附分子1 信号转导和转录 激活因子6 哮喘 

分 类 号：R562.25[医药卫生—呼吸系统]